MLchartDataset catalogue

Bosentan

Term · Oncology and biomedicine · MLC-T-ONC-012071

A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan decreases both pulmonary and systemic vascular resistance and is particularly used in the treatment of pulmonary arterial hypertension.

Table 1. Record
IdentifierMLC-T-ONC-012071
FieldOncology and biomedicine
Synonymsbosentan monohydrate
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012071",
  "term": "Bosentan",
  "field": "Oncology and biomedicine",
  "definition": "A sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan decreases both pulmonary and systemic vascular resistance and is particularly used in the treatment of pulmonary arterial hypertension.",
  "synonyms": [
    "bosentan monohydrate"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bosentan/"
}

Record 3,745 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.